Anika Therapeutics Announces Exclusive Canadian Distribution Agreement for ELEVESS(R) with Canderm Pharma Inc.

BEDFORD, Mass.--(BUSINESS WIRE)--Anika Therapeutics, Inc. (NASDAQ:ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, announced today that it has signed an exclusive agreement with Canderm Pharma, Inc., Canada’s leading independent skincare company, to distribute and market ELEVESS throughout Canada. ELEVESS is an injectable filler that reduces the appearance of lines and wrinkles on the face, and was the first HA-based dermal filler approved by the U.S. Food and Drug Administration to incorporate the anesthetic lidocaine to improve patient comfort.